TABLE V.
Analysis of the relationship between EoE status and sIgE and sIgG4 titers to CM proteins
| Prevalence of sIgE or sIgG4, no. (%) | |||||
|---|---|---|---|---|---|
| CM protein | Assay result | Patients with EoE (n = 71) | Control subjects (n = 210) | P value* | OR (95% CI) |
| Bos d 4 | sIgE ≥0.10 IU/mL | 39 (55) | 26 (12) | <.001 | 8.6 (4.6–16) |
| sIgG4 ≥0.07 μg/mL | 65 (92) | 146 (70) | <.001 | 4.7 (2.0–12) | |
| sIgG4 ≥1.00 μg/mL | 55 (77) | 87 (41) | <.001 | 4.9 (2.6–9.0) | |
| sIgG4 ≥10.0 μg/mL | 31 (44) | 21 (10) | <.001 | 7.0 (3.6–13) | |
| Bos d 5 | sIgE ≥0.10 IU/mL | 42 (59) | 38 (18) | <.001 | 6.6 (3.6–12) |
| sIgG4 ≥0.07 μg/mL | 68 (96) | 184 (88) | .07 | 3.2 (0.94–11) | |
| sIgG4 ≥1.00 μg/mL | 62 (87) | 135 (64) | <.001 | 3.8 (1.8–8.1) | |
| sIgG4 ≥10.0 μg/mL | 40 (56) | 40 (19) | <.001 | 5.5 (3.1–9.8) | |
| Bos d 8 | sIgE ≥0.10 IU/mL | 38 (54) | 32 (15) | <.001 | 6.4 (3.4–12) |
| sIgG4 ≥0.07 μg/mL | 68 (96) | 204 (97) | .70 | 0.7 (0.2–2.7) | |
| sIgG4 ≥1.00 μg/mL | 61 (86) | 114 (54) | <.001 | 5.1 (2.5–11) | |
| sIgG4 ≥10.0 μg/mL | 36 (51) | 23 (11) | <.001 | 8.4 (4.3–15) | |
*
P values were calculated by using the χ2 or Fisher exact test.